Tandem Diabetes Care Launches Innovative t:slim X2 Pump with Abbott Sensor

Tandem Diabetes Care, Inc. has announced the integration of its t:slim X2 insulin pump with the Abbott FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor, now available in the United States. This development marks a significant advancement in diabetes management, allowing users to benefit from enhanced automation and real-time glucose data.

The t:slim X2 features the advanced Control-IQ+ automated insulin delivery (AID) technology, which is designed to improve blood sugar control. By combining this with the FreeStyle Libre 3 Plus, recognized as the world’s smallest CGM, Tandem aims to provide a more seamless and personalized experience for individuals living with diabetes.

Key Features of the Integrated System

The integration of the t:slim X2 with the FreeStyle Libre 3 Plus sensor brings several notable technological advancements. The sensor boasts an extended wear time of 15 days, allowing for longer periods between replacements. It provides real-time data, transmitting automatic glucose readings every minute directly to the insulin pump.

The Control-IQ+ technology further enhances user experience by adjusting insulin delivery every five minutes based on predicted glucose values. Additionally, the system features an AutoBolus capability, which automatically calculates and delivers correction boluses. This function minimizes the impact of missed meal boluses, thereby easing the management of diabetes for users.

John Sheridan, the president and chief executive officer of Tandem Diabetes Care, emphasized the significance of this integration. He stated, “It combines Control-IQ+, our most advanced algorithm ever, together with the benefits of Abbott’s latest CGM sensor on our tested and trusted t:slim X2 insulin pump.” This sentiment underscores Tandem’s commitment to improving diabetes care through technological innovation.

Global Rollout and User Accessibility

The new compatibility feature is available immediately in the United States. All new shipments of the t:slim X2 insulin pump will come preloaded with the integration, while eligible current users can access this update through a free remote software upgrade.

Tandem aims to facilitate the transition by reaching out to eligible t:slim X2 users via email, providing instructions on how to enable the new compatibility feature. Looking ahead, the company plans to initiate early-access programs for the integrated technologies internationally before the end of the year. Full commercial availability is expected to expand throughout 2026.

This integration not only enhances the functionality of the t:slim X2 but also expands options for diabetes management, offering users greater flexibility and control over their health. With this launch, Tandem Diabetes Care reaffirms its position as a leader in innovative diabetes management solutions.